#ASH20: As Bristol Myers awaits FDA word, the CAR-T BCMA leaders go head-to-head once again. This time, they're not alone
In 2017, when Nanjing’s Legend Biotech first parachuted onto ASCO with stunning BCMA CAR-T data, bluebird bio, the incumbents in the field, immediately criticized their trial: “It’s a very different patient population,” bluebird chief Nick Leschly said at the time.
Three years and multiple rounds of confirmatory Legend data later, leadership at Bristol Myers Squibb, which took the lead on bluebird’s ide-cel following their Celgene buyout, offer a different tune when asked about competitors.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,500+ biopharma pros reading Endpoints daily — and it's free.